TrialThe Lancet. Neurology2017

Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial.

Dennis Chan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.